Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
The company was incorporated in 1988 and is based in Tarrytown, New York.
| Country | United States |
| Founded | 1988 |
| IPO Date | Apr 2, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15,410 |
| CEO | Leonard Schleifer |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 United States | |
| Phone | 914 847 7000 |
| Website | regeneron.com |
Stock Details
| Ticker Symbol | REGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000872589 |
| CUSIP Number | 75886F107 |
| ISIN Number | US75886F1075 |
| Employer ID | 13-3444607 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Co-Chairman |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer and Co-Chairman |
| Christopher R. Fenimore CPA | Executive Vice President of Finance and Chief Financial Officer |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research and Co-Chief Scientific Officer |
| Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations and Product Supply |
| Rajesh Ahuja | Senior Vice President of Quality Assurance and Operations |
| Ryan Crowe | Senior Vice President of Investor Relations and Strategic Analysis |
| Joseph J. LaRosa J.D. | Executive Vice President, General Counsel and Secretary |
| Melissa Lozner | Senior Vice President and Chief Compliance Officer |
| Sally A. Paull | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 9, 2026 | 144 | Filing |
| Feb 9, 2026 | 144 | Filing |
| Feb 6, 2026 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Feb 4, 2026 | 10-K | Annual Report |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 144 | Filing |
| Nov 20, 2025 | 144 | Filing |
| Nov 7, 2025 | 144 | Filing |
| Nov 7, 2025 | 13F-HR | Quarterly report filed by institutional managers, holdings |